EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Robust Bioconjugated Antigens Induce Immune Responses Preventing Malaria Infection and its Transmission

Nivethika Sivakumaran, Yevel Flores-Garcia, Chanel M Naar, Shuxiong Chen, Mili Mehta, Fijs W B van Leeuwen, Abhai Tripathi, Rajagopal Murugan, Meta Roestenberg, Fidel Zavala, Bernd H A Rehm iD

Small · 2026

DOI: 10.1002/smll.202508762 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Small, 2026. Verfasst von Nivethika Sivakumaran und 10 weiteren Autor:innen. Beteiligte Einrichtung: Centre For Cell Factories and Biopolymers, Institute For Biomedicine and Glycomics, Griffith University, Nathan, Australia. Hauptthemen laut MEDLINE: Malaria Vaccines, Malaria, Antigens, Protozoan. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 111 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Foundation for the National Institutes of Health, Centre for Cell Factories and Biopolymers at Griffith University, Griffith Institute for Biomedicine and Glycomics at Griffith University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Malaria remains a major global health challenge, with current vaccines providing only limited reductions in case numbers. This study introduces an innovative approach that utilizes engineered Escherichia coli to bioconjugate and assemble the pre‐erythrocytic circumsporozoite protein‐derived RTS,S antigen and the sexual‐stage Pfs47 subdomain into biopolymer particles (BPs), generating the dual‐antigen Pfs47‐RTS,S‐BP vaccine. Compared to single‐antigen BPs, the fused Pfs47‐RTS,S‐BP formulation shows synergistic enhancement in immunogenicity and protective efficacy. Pfs47‑RTS,S‑BP retains its physical properties and antigenicity after storage at 37°C. Although functional in vivo assessment of these thermostable formulations has not yet been performed, the findings indicate promising thermostability that could help overcome cold‑chain limitations in malaria‑endemic regions. Pfs47‐RTS,S‐BP induces durable antibody and T cell responses alongside crucial liver‐resident memory T cells for frontline defence. Vaccine‐induced antibodies efficiently neutralize sporozoites and inhibit parasite transmission. Pfs47‐RTS,S‐BP generates RTS,S‐specific antibody levels 5.3‐fold higher than the protective thresholds of the current RTS,S/AS01 vaccine. The Pfs47‐RTS,S‐BP formulation also achieves 80.4% protection against mosquito bite challenge and 68.15% transmission‐reducing activity, demonstrating strong potential as a robust, dual‐stage malaria vaccine candidate. Overall, this work underscores the potential of Pfs47‑RTS, S‑BP to overcome key limitations of current vaccines and to substantially advance global malaria control efforts.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Malaria VaccinesMalariaAntigens, ProtozoanAnimalsProtozoan ProteinsSporozoitesAntibodies, ProtozoanHumansPlasmodium falciparumFemale

Stichwörter der Autor:innen

bioconjugated antigensbiopolymer particlesdual‐stage immunitymalaria vaccinessporozoite‐neutralising antibodiesthermostable vaccines transmission‐blocking antibodies

Substanzen

Malaria VaccinesAntigens, ProtozoanProtozoan ProteinsAntibodies, Protozoan

Autor:innen und Institutionen

  • Centre For Cell Factories and Biopolymers, Institute For Biomedicine and Glycomics, Griffith University, Nathan, Australia.
  • W. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA.
  • Johns Hopkins Malaria Research Institute, Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA.
  • Leiden University Center For Infectious Diseases (LUCID), Leiden University Medical Center, Leiden, The Netherlands.
  • Interventional Molecular Imaging Laboratory, Leiden University Medical Center, Leiden, The Netherlands.

ORCID-Profile: Bernd H A Rehm

Förderung

  • Foundation for the National Institutes of Health
  • Centre for Cell Factories and Biopolymers at Griffith University
  • Griffith Institute for Biomedicine and Glycomics at Griffith University
  • Australian Research Council
  • NIAID NIH HHS

Zitieren

APA

Sivakumaran, N., Flores-Garcia, Y., Naar, C. M., Chen, S., Mehta, M., van Leeuwen, F. W. B., Tripathi, A., Murugan, R., Roestenberg, M., Zavala, F., & Rehm, B. H. A. (2026). Robust Bioconjugated Antigens Induce Immune Responses Preventing Malaria Infection and its Transmission. Small. https://doi.org/10.1002/smll.202508762

Vancouver

Sivakumaran N, Flores-Garcia Y, Naar CM, Chen S, Mehta M, van Leeuwen FWB, et al. Robust Bioconjugated Antigens Induce Immune Responses Preventing Malaria Infection and its Transmission. Small. 2026. doi:10.1002/smll.202508762

BibTeX
@article{Sivakumaran2026,
  author = {Sivakumaran, Nivethika and Flores-Garcia, Yevel and Naar, Chanel M and Chen, Shuxiong and Mehta, Mili and van Leeuwen, Fijs W B and Tripathi, Abhai and Murugan, Rajagopal and Roestenberg, Meta and Zavala, Fidel and Rehm, Bernd H A},
  title = {Robust Bioconjugated Antigens Induce Immune Responses Preventing Malaria Infection and its Transmission},
  journal = {Small},
  year = {2026},
  doi = {10.1002/smll.202508762}
}
Kostenlos starten →